Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis

被引:139
|
作者
Selvaag, Anne M. [1 ]
Aulie, Hanne A. [1 ]
Lilleby, Vibke [1 ]
Flato, Berit [1 ,2 ]
机构
[1] Oslo Univ Hosp, Dept Rheumatol, N-0424 Oslo, Norway
[2] Univ Oslo, Fac Med, Inst Clin Med, Oslo, Norway
关键词
QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; CLINICAL REMISSION; ACTIVITY SCORE; FOLLOW-UP; PROGNOSTIC-FACTORS; SELECT CATEGORIES; INACTIVE DISEASE; COHORT; CHILDREN;
D O I
10.1136/annrheumdis-2014-206034
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe disease activity 30 years after disease onset in a previously studied cohort of patients with juvenile idiopathic arthritis (JIA) and reveal predictors of long-term active disease. Methods Patients with JIA, first referred 1980-1985 and re-examined 15 and 23 years after onset, were invited to attend. All 176 patients were assessed by questionnaires. Patients with signs of active disease at 15 years or later also came to a clinical re-examination (n=90). Disease activity was assessed by the clinical juvenile arthritis disease activity score (JADAS3) and by the criteria for remission in JIA, and health status by Health Assessment Questionnaire (HAQ) and Medical Outcome Study 36-item Short Form Health Survey (SF-36). Results At 30-year follow-up, 59% of the patients were in clinical remission off medication, 7% were in remission on medication and 34% had active disease. 70% of the patients were in the same category of disease activity at 15 and 30 years. The JADAS3 was <= 2.0 in 54%, 2.1-4.5 in 18% and >4.5 in 28%. HLA-DRB1*01, physician's global assessment and a short total time in remission at 15 years, predicted active disease. Physician's global assessment also predicted a JADAS3 >4.5. From 15 to 30 years (n=90), physician's global assessment, number of active joints, erythrocyte sedimentation rate and C reactive protein improved significantly, but patient's global assessment, HAQ and SF-36 did not. Conclusions 41% of the patients with JIA had active disease or were on medication after 30 years and 28% had a high symptom state. Remission rates and patient-reported health status at 15 years were comparable with rates at 30 years.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 50 条
  • [1] Long-Term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis The Importance of Definition
    Shoop-Worrall, Stephanie J. W.
    Verstappen, Suzanne M. M.
    McDonagh, Janet E.
    Baildam, Eileen
    Chieng, Alice
    Davidson, Joyce
    Foster, Helen
    Ioannou, Yiannis
    McErlane, Flora
    Wedderburn, Lucy R.
    Thomson, W.
    Hyrich, Kimme L.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (09) : 1519 - 1529
  • [2] Ongoing Disease Activity and Changing Categories in a Long-Term Nordic Cohort Study of Juvenile Idiopathic Arthritis
    Nordal, Ellen
    Zak, Marek
    Aalto, Kristiina
    Berntson, Lillemor
    Fasth, Anders
    Herlin, Troels
    Lahdenne, Pekka
    Nielsen, Susan
    Straume, Bjorn
    Rygg, Marite
    ARTHRITIS AND RHEUMATISM, 2011, 63 (09): : 2809 - 2818
  • [3] High-sensitive CRP as a predictive marker of long-term outcome in juvenile idiopathic arthritis
    Alberdi-Saugstrup, Mikel
    Zak, Marek
    Nielsen, Susan
    Herlin, Troels
    Nordal, Ellen
    Berntson, Lillemor
    Fasth, Anders
    Rygg, Marite
    Mueller, Klaus
    RHEUMATOLOGY INTERNATIONAL, 2017, 37 (05) : 695 - 703
  • [4] Inflammatory Markers and Disease Activity in Juvenile Idiopathic Arthritis
    Sarkar, Sumantra
    Alam, Md. Mahboob
    Das, Gargi
    Datta, Supratim
    INDIAN JOURNAL OF PEDIATRICS, 2017, 84 (05) : 349 - 356
  • [5] A lifelong journey: Long-term perspectives on Juvenile Idiopathic Arthritis
    Ramos, Filipa Oliveira
    Zinterl, Carolina
    Fonseca, Joao Eurico
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2024, 38 (03):
  • [6] Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment
    Nalbanti, Panayiota
    Kanakoudi-Tsakalidou, Florentia
    Trachana, Maria
    Pratsidou-Gertsi, Polyxeni
    Farmaki, Evangelia
    Bamidis, Panagiotis
    Papachristou, Fotios
    RHEUMATOLOGY INTERNATIONAL, 2018, 38 (07) : 1241 - 1250
  • [7] Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes
    Su, Yueh
    Yang, Yao-Hsu
    Chiang, Bor-Luen
    CLINICAL RHEUMATOLOGY, 2017, 36 (09) : 1997 - 2004
  • [8] Predictors and long-term outcome in Greek adults with juvenile idiopathic arthritis: a 17-year continuous follow-up study
    Dimopoulou, Despoina
    Trachana, Maria
    Pratsidou-Gertsi, Polyxeni
    Sidiropoulos, Prodromos
    Kanakoudi-Tsakalidou, Florentia
    Dimitroulas, Theodoros
    Garyfallos, Alexandros
    RHEUMATOLOGY, 2017, 56 (11) : 1928 - 1938
  • [9] Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score
    Consolaro, Alessandro
    Bracciolini, Giulia
    Ruperto, Nicolino
    Pistorio, Angela
    Magni-Manzoni, Silvia
    Malattia, Clara
    Pederzoli, Silvia
    Davi, Sergio
    Martini, Alberto
    Ravelli, Angelo
    ARTHRITIS AND RHEUMATISM, 2012, 64 (07): : 2366 - 2374
  • [10] Disease Activity and Fatigue in Juvenile Idiopathic Arthritis
    Ringold, Sarah
    Ward, Teresa M.
    Wallace, Carol A.
    ARTHRITIS CARE & RESEARCH, 2013, 65 (03) : 391 - 397